Ocugen Balances European Expansion Against Legal Scrutiny and Insider Selling

Halper Sadeh opens a preliminary Ocugen investigation, the company names an Amsterdam-based European GM, and the CEO files notice to sell shares.

Ocugen finds itself navigating a familiar paradox for clinical-stage biotechs: scientific progress on one front, capital-market pressure on another. The Pennsylvania-based gene therapy developer is simultaneously building out its European footprint, advancing its pipeline toward late-stage trials, and fielding a fresh legal inquiry — all while its share price continues to slide.

A Legal Review, Not a Lawsuit

Halper Sadeh LLP, a US law firm, has opened an investigation into Ocugen's officers and board members. At issue is whether corporate fiduciaries may have breached their duties to shareholders. The firm was explicit that this is a preliminary inquiry — not a filed complaint, and not evidence of any wrongdoing. For Ocugen, the probe arrives during a stretch defined by pivotal clinical decisions and an international push.

Amsterdam as the European Beachhead

That international push now has a physical address. Ocugen appointed Jolanda Crombach as General Manager of its European subsidiary, based in Amsterdam. Her mandate extends beyond regulatory paperwork: she is tasked with coordinating marketing-authorization applications and development milestones for OCU410, while also laying the groundwork for potential commercial operations across the continent.

The appointment, announced roughly a week ago, positions Crombach to shepherd three gene therapy programs through Phase 3. The company has signaled that key readouts from these programs will not arrive until 2027 and 2028. More immediate data exists — twelve-month results from the Phase 2 ArMaDa study of OCU410 were available about three weeks ago — but such interim milestones do little to shorten the wait for late-stage results.

Insider Filing Draws Attention

On the leadership front, CEO Shankar Musunuri filed a notice with the SEC indicating his intent to sell 525,991 Ocugen shares through Merrill Lynch. The stated aggregate value of the securities was $497,964.91. A Form 144 represents advance notice of a proposed sale — not confirmation that a transaction has been completed.

Market Under Pressure

The stock's performance reflects the broader strain. In European trading on Tuesday, the shares added 1.9% to reach EUR 0.8660, yet remain down 31% since the start of the year. The prior session's close in European trading was EUR 0.8500, a modest daily decline of 0.4%, with the year-to-date loss at that point standing at 32%.

Whether Halper Sadeh's review escalates into concrete legal action remains unclear. What matters more for Ocugen's trajectory, arguably, are the next steps in its regulatory filings and the continued clinical progress of OCU410. Until those catalysts materialize, the company's scientific ambitions will keep being measured against the unsparing standards of the public markets.